Product
Fenretinide
3 clinical trials
14 indications
Indication
Safety and TolerabilityIndication
T-cell LymphomaIndication
Cutaneous T-Cell LymphomaIndication
Peripheral T-cell LymphomaIndication
Peripheral T-Cell LymphomaIndication
Not ClassifiedIndication
Primary Cutaneous T-cell LymphomaIndication
UnspecifiedIndication
Cutaneous T-cell LymphomaIndication
Follicular T-Cell LymphomaIndication
Angioimmunoblastic T-cell LymphomaIndication
Sézary's DiseaseIndication
Mycosis FungoidesIndication
NeuroblastomaClinical trial
A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2024-02-13
Clinical trial
An Exploratory Clinical Study to Investigate the Effect of autoSTEM-OA and alloSTEM-OA in Participants With Knee Osteoarthritis.Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant NeuroblastomaStatus: Completed, Estimated PCD: 2014-03-01